VERARING Drug Patent Profile
✉ Email this page to a colleague
When do Veraring patents expire, and what generic alternatives are available?
Veraring is a drug marketed by Dr Reddys Labs Sa and is included in one NDA.
The generic ingredient in VERARING is ethinyl estradiol; etonogestrel. There are twenty-six drug master file entries for this compound. Nine suppliers are listed for this compound. Additional details are available on the ethinyl estradiol; etonogestrel profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Veraring
A generic version of VERARING was approved as ethinyl estradiol; etonogestrel by TEVA PHARMS USA INC on January 13th, 2021.
AI Deep Research
Questions you can ask:
- What is the 5 year forecast for VERARING?
- What are the global sales for VERARING?
- What is Average Wholesale Price for VERARING?
Summary for VERARING
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| Patent Applications: | 168 |
| DailyMed Link: | VERARING at DailyMed |
US Patents and Regulatory Information for VERARING
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Dr Reddys Labs Sa | VERARING | ethinyl estradiol; etonogestrel | RING;VAGINAL | 207577-001 | Dec 9, 2021 | DISCN | No | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
